Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-07-12
2005-07-12
Russel, Jeffrey Edwin (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S008100, C514S012200
Reexamination Certificate
active
06916790
ABSTRACT:
A substantially pure complex including IGFIIE polypeptide and IGFBP2 polypeptide is described. Methods for treating an osteoporosis patient and targeting a compound to the skeletal extracellular matrix of a patient are also described.
REFERENCES:
patent: 5187151 (1993-02-01), Clark et al.
patent: 5569648 (1996-10-01), Lewis et al.
patent: 5681818 (1997-10-01), Spencer et al.
patent: 5998369 (1999-12-01), Khosla et al.
patent: 0 259 904 (1988-03-01), None
patent: 0289314 (1988-11-01), None
patent: WO 94/04030 (1994-03-01), None
patent: WO 96/02565 (1996-02-01), None
patent: WO 98/50428 (1998-11-01), None
patent: WO 01/30811 (2001-05-01), None
Bach et al. Biochim. Biophys. Acta. vol. 1313, pp. 79-88 (1996).
Adams et al.,Endocrine Society, 1997 Meeting, p. 496, Abstract P3-240.
Agarwal et al., “Sequence Analysis, Expression and Chromosomal Localization of a Gene, Isolated From a Substracted Human Retina cDNA Library, That Encodes an Insulin-like Growth Factor Binding Protein (IGFPP2),”Exp. Eye Res., 1991, 52(5):549-561.
Arai et al., “Binding of Insulin-Like Growth Factor (IGF) I or II to IGF-Binding Protein-2 Enables It to Bind to Heparin and Extracellular Matrix,”Endocrinology, 1996, 137(11):4571-4575.
Bell et al., “Sequence of a cDNA clone encoding human preproinsulin-like growth factor II,”Nature, 1984, 310:775-777.
Beyer et al., “Case Report—Idiopathic Acquired Diffuse Osteosclerosis in a Young Woman,”J. Bone Mineral Res., 1990, 5(12):1257-1263.
Conover, “A Unique Receptor-independent Mechanism by which Insulinlike Growth Factor I Regulates the Availability of Insulinlike Growth Factor Binding Proteins in Normal and Transformed Human Fibroblasts,”J. Clin. Invest., 1991, 88:1354-1361.
Conover, “The Role of Insulin-like Growth Factors and Binding Proteins in Bone Cell Biology,”Principles of Bone Biology, 1996, 43:607-618.
Diamond and Depczynski, “Acquired Osteosclerosis Associated with Intravenous Drug Use and Hepatitis C Infection,”Bone, 1996, 19(6):679-683.
Duguay et al., “Post-translational Processing of the Insulin-like Growth Factor-2 Precursor,”J. Biol. Chem., 1998, 273(29):18443-18451.
Dull et al., “Insulin-like growth factor II precursor gene organization in relation to insulin gene family,”Nature, 1984, 310:777-781.
Durham et al., “Regulation of Insulin-like Growth Factor Binding Protein 4 by a Spectral Insulin-like Growth Factor Binding Protein 4 Proteinase in Normal Human Osteoblast-like Cells: Implications in Bone Cell Physiology,”J. Bone Mineral Res., 1994, 9(1):111-117.
Ebeling et al., “Short-Term Effects of Recombinant Human Insulin-Like Growth Factor I on Bone Turnover in Normal Women,”J. Clin. Endocrinol. Metab., 1993, 77(5):1384-1387.
Ghiron et al., “Effects of Recombinant Insulin-like Growth Factor-1 and Growth Hormone on Bone Turnover in Elderly Women,”J. Bone Mineral Res., 1995, 10(12):1844-1852.
Glaser and Kaplan, “Osteoporosis—Definition and Clinical Presentation,”Spine, 1997, 22(24S):12S-16S.
Harris et al., “Development and Characterization of a Conditionally Immortalized Human Fetal Osteoblastic Cell Line,”J. Bone Mineral Res., 1995, 10(2):178-186.
Hassager et al., “Basal and Regulated Secretion of Insulin-Like Growth Factor Binding Proteins in Osteoblast-Like Cells is Cell Line Specific,”J. Clin. Endocrinol. Metab., 1992, 75(1):228-233.
Hassoun et al., “Hepatitis C—associated Osteosclerosis: An Unusual Syndrome of Acquired Osteosclerosis in Adults,”Am. J. Med., 1997, 103(1):70-73.
Hossenlopp et al., “Analysis of Serum Insulin-like Growth Factor Binding Proteins Using Western Blotting: Use of the Method for Titration of the Binding Proteins and Competitive Binding Studies,”Anal. Biochem., 1986, 154(1):138-143.
Khosla et al., “Insulin-like Growth Factor System Abnormalities in Hepatitis C-associated Osteosclerosis,”J. Clin. Invest., 101(10):2165-2173 (May 1998).
Le Roith, “Insulin-Like Growth Factors,”Seminars in Medicine of the Beth Israel Deaconess Medical Center, 1997, 336(9):633-640.
Liu et al., “Characterization of the High Molecular Weight Insulin-Like Growth Factor Complex in Term Pregnancy Serum,”J. Clin. Endocrinol. Metab., 1992, 75(5):1261-1267.
Liu et al., “Characterization of Proinsulin-Like Growth Factor-II E-Region Immunoreactivity in Serum and Other Biological Fluids,”J. Clin. Endocrinol. Metab., 1993, 76(5):1095-1100.
McKinnon et al., “Expression, purification and characterization of secreted recombinant human insulin-like growth factor-I (IGF-I) and the potent variant des(1-3)IGF-I in Chinese hamster ovary cells,”J. Mol. Endocrinol., 1991, 6(3):231-239.
Powell et al., “Serum Somatomedin Levels in Adults with Chronic Renal Failure: The Importance of Measuring Insulin-Like Growth Factor I (IGF-I) and IGF-II in Acid-Chromatographed Uremic Serum,”J. Clin. Endocrinol. Metab., 1986, 63(5):1186-1192.
Robey and Termine, “Human Bone Cells In Vitro,”Calcif. Tissue Int., 1985, 37:453-460.
Upton et al., “Characterization and cloning of a bovine insulin-like growth factor-binding protein,”J. Mol. Endocrinol., 1990, 5(1):77-84.
Valenzano et al., “Biophysical and Biological Properties of Naturally Occurring High Molecular Weight Insulin-like Growth Factor II Variants,”J. Biol. Chem., 1997, 272(8):4804-4813.
Villareal et al., “Painful Diffuse Osteoschlerosis After Intraveneous Drug Abuse,”Am. J. Med., 1992, 93:371-381.
Whitfield et al., “Isolation of a cDNA clone encoding rat insulin-like growth factor-II precursor,”Nature, 1984, 312:277-280.
Whyte et al., “Diffuse Osteosclerosis in Intravenous Drug Abusers,”Am. J. Med., 1993, 95:660-662.
Whyte et al., “Doubling Skeletal Mass During Adult Life: The Syndrome of Diffuse Osteosclerosis after Intravenous Drug Abuse,”J. Bone Mineral Res., 1996, 11(4):554-558.
Whyte and Reasner, “Hepatitis C-associated Osteosclerosis after Blood Transfusion,”Am. J. Med., 1997, 102:219-220.
Yang et al., “The Expression and Characterization of Human Recombinant Proinsulin-Like Growth Factor II and a Mutant That Is Defective in the O-Glycosylation of Its E Domain,”Endocrinology, 1996, 137(7):2766-2773.
Ballard Francis J.
Conover Cheryl A.
Khosla Sundeep
Tapley Peter M.
Fish & Richardson P.C. P.A.
Mayo Foundation for Medical Education and Research
Russel Jeffrey Edwin
LandOfFree
Treatment of osteoporosis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of osteoporosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of osteoporosis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3431565